ArticleJournal of cellular and molecular medicine2019
Isorhamnetin attenuates osteoarthritis by inhibiting osteoclastogenesis and protecting chondrocytes through modulating reactive oxygen species homeostasis.
Article in Journal of cellular and molecular medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 54 citations in OpenAlex.
- Classification, Structure-Activity Relationship, and Anti-Osteoarthritis Mechanism of Natural Flavonoids.Chemistry & biodiversity · 2026Review
- Integrated analysis of single-cell RNA sequencing, transcriptomics, and thermal proteome profiling identifies PLCG1 as the therapeutic target of isopimpinellin in treating rheumatoid arthritis.Cellular & molecular biology letters · 2026Article
- Isorhamnetin inhibits mechanical stress-induced chondrocyte apoptosis through activation of the ROS/SRC/FOXO1 signaling pathway.Scientific reports · 2026Article
- Repurposing metformin for treating osteoarthritis via leveraging Nrf2 signaling.Scientific reports · 2026Article
- Fecal microbiota and metabolite profiles in patients with osteoarthritis: a cross-sectional study.Frontiers in cellular and infection microbiology · 2026Article
- Sea buckthorn berry extract favorably affects bone metabolism-related biomarkers and collagen deposition in cultured rat primary osteoblasts.Open life sciences · 2026Article
- Mechanisms of isorhamnetin inhibition of osteoclast differentiation: insights from molecular dynamics simulations andFrontiers in pharmacology · 2025Article
- Natural Polyphenols and Mesenchymal Stem Cells: A New Insight in Bone Regenerative Medicine.Stem cells international · 2025Review
- Exploring the Potential Mechanisms of Zuo Gui Pill for the Treatment of Knee Osteoarthritis based on Network Pharmacology and Molecular Docking Techniques.Current pharmaceutical design · 2025Article
- Interleukin-37 Inhibits Interleukin-1β-Induced Articular Chondrocyte Apoptosis by Suppressing Reactive Oxygen Species.Biomedicines · 2024Article
- Subchondral osteoclasts and osteoarthritis: new insights and potential therapeutic avenues.Acta biochimica et biophysica Sinica · 2024Review
- Recent advances of NFATc1 in rheumatoid arthritis-related bone destruction: mechanisms and potential therapeutic targets.Molecular medicine (Cambridge, Mass.) · 2024Review
- Exosomal communication: a pivotal regulator of bone homeostasis and a potential therapeutic target.Frontiers in pharmacology · 2024Review
- Sea buckthorn and its flavonoids isorhamnetin, quercetin, and kaempferol favorably influence bone and breast tissue health.Frontiers in pharmacology · 2024Review
- Unveiling the potential of Butylphthalide: inhibiting osteoclastogenesis and preventing bone loss.Frontiers in pharmacology · 2024Article
- Risk of metabolic abnormalities in osteoarthritis: a new perspective to understand its pathological mechanisms.Bone research · 2023Review
- Anti-Osteoporotic Potential of Water Extract ofNutrients · 2023Article
- Zuo Gui Wan Promotes Osteogenesis via PI3K/AKT Signaling Pathway: Network Pharmacology Analysis and Experimental Validation.Current medical science · 2023Article
- Alisol A 24-acetate ameliorates osteoarthritis progression by inhibiting reactive oxygen species and inflammatory response through the AMPK/mTOR pathway.Immunity, inflammation and disease · 2023Article
- Bioactivity, Molecular Mechanism, and Targeted Delivery of Flavonoids for Bone Loss.Nutrients · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Increasing evidence indicates that osteoarthritis (OA) is a musculoskeletal disease affecting the whole joint, including both cartilage and subchondral bone. Reactive oxygen species (ROS) have been demonstrated to be one of the important destructive factors during early-stage OA development. The objective of this study was to investigate isorhamnetin (Iso) treatment on osteoclast formation and chondrocyte protection to attenuate OA by modulating ROS. Receptor activator of nuclear factor-kappa B ligand (RANKL) was used to establish the osteoclast differentiation model in bone marrow macrophages (BMMs) in vivo. H
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.